Table 1. Baseline characteristics and drug treatments of 310 patients with ruptured intracranial aneurysms and 887 patients with unruptured intracranial aneurysms.
| Characteristics | Ruptured IA (n = 310)* | Unruptured IA (n = 887)* | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | |||
| Age, y (SD) | 63.2 (16.0) | 62.8 (10.6) | 1.00 | 0.99–1.01 | 0.58 | |||
| Women, n (%) | 219 (70.7) | 577 (65.1) | 1.29 | 0.98–1.71 | 0.07 | 1.33 | 0.99–1.79 | 0.06 |
| Smokers, n (%) | 139 (44.8) | 426 (48.0) | 0.88 | 0.68–1.14 | 0.33 | |||
| History of aSAH, n (%) | 11 (3.6) | 51 (5.8) | 0.60 | 0.31–1.17 | 0.13 | 0.53 | 0.26–1.09 | 0.09 |
| Familial history of aSAH, n (%) | 32 (10.3) | 169 (19.1) | 0.49 | 0.33–0.73 | 0.0004 | 0.5 | 0.33–0.76 | 0.001 |
| Size, mm (SD) | 7.0 (3.9) | 6.5 (4.3) | 1.02 | 0.99–1.05 | 0.10 | 1.03 | 1.00–1.06 | 0.049 |
| Calcium channel blockers | 63 (20.3) | 368 (41.5) | 0.36 | 0.26–0.49 | < 0.0001 | 0.41 | 0.30–0.58 | < 0.0001 |
| Angiotensin II receptor blockers | 73 (23.6) | 336 (37.9) | 0.51 | 0.38–0.68 | < 0.0001 | 0.67 | 0.48–0.93 | 0.02 |
| Angiotensin-converting enzyme inhibitors | 8 (2.6) | 27 (3.0) | 0.84 | 0.38–1.88 | 0.68 | - | - | - |
| Renin inhibitors | 1 (0.3) | 3 (0.3) | 0.95 | 0.01–9.20 | 1.00 | - | - | - |
| Thiazide/Indapamide | 12 (3.9) | 51 (5.8) | 0.66 | 0.35–1.26 | 0.20 | - | - | - |
| β-adrenergic receptor blockers | 24 (7.7) | 78 (8.8) | 0.87 | 0.54–1.40 | 0.57 | - | - | - |
| HMG-CoA reductase inhibitors (statins) | 50 (16.1) | 268 (30.2) | 0.44 | 0.32–0.62 | < 0.0001 | 0.54 | 0.38–0.77 | 0.0008 |
| Eicosapentaenoic acid | 8 (2.6) | 28 (3.2) | 0.81 | 0.37–1.80 | 0.61 | - | - | - |
| Dipeptidyl peptidase-4 inhibitors | 9 (2.9) | 42 (4.7) | 0.60 | 0.29–1.25 | 0.17 | 0.99 | 0.46–2.16 | 0.99 |
| Peroxisome proliferator-activated receptor γ agonists | 2 (0.7) | 11 (1.2) | 0.52 | 0.11–2.35 | 0.53 | - | - | - |
| Biguanides | 4 (1.3) | 17 (1.9) | 0.67 | 0.22–2.00 | 0.47 | - | - | - |
| Selective serotonin reuptake inhibitors | 5 (1.6) | 15 (1.7) | 0.95 | 0.34–2.64 | 0.93 | - | - | - |
| Glucocorticoids | 10 (3.2) | 17 (1.9) | 1.70 | 0.77–3.77 | 0.18 | 1.75 | 0.73–4.21 | 0.21 |
| Non-aspirin non-steroidal anti-inflammatory drugs | 24 (7.7) | 23 (2.6) | 3.15 | 1.75–5.67 | < 0.0001 | 3.24 | 1.71–6.13 | 0.0003 |
| Selective COX-2 inhibitors | 8 (2.6) | 15 (1.7) | 1.54 | 0.65–3.67 | 0.33 | - | - | - |
| Selective estrogen receptor modulators | 1 (0.3) | 11 (1.2) | 0.26 | 0.03–2.00 | 0.32 | - | - | - |
| Anticoagulants | 6 (1.9) | 20 (2.3) | 0.86 | 0.34–2.15 | 0.74 | - | - | - |
*Data are shown as the n (%) or mean (standard deviation).
Abbreviations; CI = confidence interval, IA = intracranial aneurysm, OR = odds ratio, SD = standard deviation, aSAH = aneurysmal subarachnoid hemorrhage, HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A, COX = cyclooxygenase.